Medpace Holdings (MEDP) Receives Daily Media Impact Score of 0.35
Media stories about Medpace Holdings (NASDAQ:MEDP) have trended positive recently, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medpace Holdings earned a news impact score of 0.35 on Accern’s scale. Accern also gave media stories about the company an impact score of 47.502974099675 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Medpace Holdings, Inc. :MEDP-US: Earnings Analysis: Q2, 2017 By the Numbers : August 4, 2017 (finance.yahoo.com)
- FY2019 EPS Estimates for Medpace Holdings, Inc. Raised by William Blair (NASDAQ:MEDP) (americanbankingnews.com)
- FY2017 EPS Estimates for Medpace Holdings, Inc. Raised by William Blair (MEDP) (americanbankingnews.com)
- Medpace Holdings, Inc. (MEDP) Receives Hold Rating from Jefferies Group LLC (americanbankingnews.com)
- Zacks: Analysts Expect Medpace Holdings, Inc. (NASDAQ:MEDP) Will Post Quarterly Sales of $95.59 Million (americanbankingnews.com)
Shares of Medpace Holdings (MEDP) opened at 31.63 on Monday. The stock has a 50 day moving average price of $28.44 and a 200-day moving average price of $29.49. The company has a market capitalization of $1.25 billion and a PE ratio of 55.69. Medpace Holdings has a 12 month low of $21.76 and a 12 month high of $38.94.
Medpace Holdings (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.08. The company had revenue of $94.60 million for the quarter, compared to analyst estimates of $92.71 million. Medpace Holdings had a net margin of 5.37% and a return on equity of 9.32%. Medpace Holdings’s revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company posted $0.45 earnings per share. Analysts forecast that Medpace Holdings will post $1.42 EPS for the current year.
MEDP has been the topic of a number of analyst reports. Jefferies Group LLC reissued a “hold” rating and issued a $35.50 price target on shares of Medpace Holdings in a research report on Friday, April 21st. Zacks Investment Research raised Medpace Holdings from a “sell” rating to a “hold” rating and set a $33.00 price target on the stock in a research report on Thursday. ValuEngine cut Medpace Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Wells Fargo & Company cut Medpace Holdings from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 3rd. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $36.00 price target (up from $35.00) on shares of Medpace Holdings in a research report on Tuesday, June 6th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $34.00.
COPYRIGHT VIOLATION NOTICE: “Medpace Holdings (MEDP) Receives Daily Media Impact Score of 0.35” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/07/medpace-holdings-medp-receives-daily-media-impact-score-of-0-35.html.
Medpace Holdings Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.